- Home
- VLYPO vs LYEL Comparison
VLYPO vs LYEL Comparison
Compare VLYPO & LYEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
VLYPO
Valley National Bancorp 5.50% Fixed-to-Floating Rate Non-Cumulative Perpetual Preferred Stock Series B
Current Price
Company Overview
Basic Information| Metric | VLYPO | LYEL |
|---|---|---|
| Founded | N/A | 2018 |
| Country | United States | United States |
| Employees | 3732 | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | N/A | 745.5M |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | VLYPO | LYEL |
|---|---|---|
| Price | $25.10 | $25.03 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $25.00 |
| AVG Volume (30 Days) | N/A | ★ 127.8K |
| Earning Date | N/A | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $41,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | N/A | $7.65 |
| 52 Week High | N/A | $45.00 |
Technical Indicators
Market Signals| Indicator | VLYPO | LYEL |
|---|---|---|
| Relative Strength Index (RSI) | 48.04 | 40.12 |
| Support Level | $24.90 | $32.01 |
| Resistance Level | $25.43 | $45.00 |
| Average True Range (ATR) | 0.19 | 3.64 |
| MACD | -0.01 | -1.63 |
| Stochastic Oscillator | 47.21 | 2.56 |
Price Performance
Historical ComparisonAbout VLYPO Valley National Bancorp 5.50% Fixed-to-Floating Rate Non-Cumulative Perpetual Preferred Stock Series B
Valley National Bancorp is a bank holding company that offers a full suite of national and regional banking solutions through various commercial, private banking, retail, insurance, and wealth management financial services products. It provides personalized service and customized solutions to assist its customers with their financial service needs. The group also offers niche financial services, including loan and deposit products for homeowners associations, cannabis-related business banking, and venture banking, which offers nationally. It manages its business operations under operating segments consisting of Consumer Banking; Commercial Banking; and Treasury and Corporate Other. The group generates the majority of its revenue from the Commercial Banking Segment.
About LYEL Lyell Immunopharma Inc.
Lyell Immunopharma Inc is a clinical-stage cell therapy company. It has a pipeline of product candidates for patients with solid tumors utilizing ex vivo genetic and epigenetic T-cell reprogramming technologies. The company's product pipeline includes, LYL797, LYL119, LYL845 among others.